These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt, with results 2008-003967-37 Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease 2012-12-10 not-yet-due
Exempt, with results 2008-007785-39 Safety and efficacy phase I/IIa trial of an RNActive®-derived cancer vaccine in stage IIIB/IV non small cell lung cancer (NSCLC) 2014-02-25 not-yet-due
Exempt, with results Terminated 2011-006314-14 A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Pros... 2017-01-19 not-yet-due
Completed, but no date, and reported results Terminated 2013-004489-32 An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer Eine unverblindete, randomisierte Phase-II-Studie mit R... bad-data
Listed as ongoing, but also has a completion date and reported results 2020-003998-22 COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Y... 2022-06-03 bad-data
Reported results 2020-004066-19 COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Wor... 2022-06-08 due-trials
Reported results 2020-004070-22 COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above with ... 2021-09-21 due-trials